Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease (NCT07627529)
Evaluating the Effect of Deprescribing Antimuscarinic Overactive Bladder Medications on Cognitive Function and Quality of Life of Individuals With Parkinson Disease: A Pharmacist-led Series of N-of-1 Trials
🩺 Plain-English Summary (8th-Grade Level)
This is an unblinded, non-randomized National Institute of Health (NIH) Stage I of Behavioral Intervention Development trial. The investigators will enroll 20 subjects with Parkinson disease (PD) for a series of 20 of N-of-1 trials. The investigators will use a single-arm crossover titration/reversal design ("ON" \[A\] vs. "OFF" \[B\]) with up to 4 periods. All participants will follow the sequence ABAB. Each period will last up to 10 weeks, allowing for sufficient time for up-titration and onset of drug action, and down-titration and washout. Each participant will have the option to participate in less (2-3) or more (3-4) periods depending on whether additional information is needed to make an informed decision about continuing or discontinuing the overactive bladder (OAB) antimuscarinic at the end of the study. The intervention drug will be an OAB antimuscarinic, previously prescribed to the participants by their physician. The investigators will reduce the dose of each OAB antimuscarinic by 25-50% every 1-2 weeks during the "OFF" \[B\] period, with the goal to completely discontinue the medication.
Who can join: Review the eligibility criteria below.
Location: Corporal Michael J. Crescenz VA Medical Center — Philadelphia, Pennsylvania
Age range: 60 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Corporal Michael J. Crescenz VA Medical Center — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (215) 823-5800
Email: Allison.Willis2@va.gov
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Parkinson Disease (PD)
- Behavioral Intervention for Lifestyle Physical Activity in Parkinson's Disease — Chicago, Illinois
- Passive Versus Active Music Therapy Parkinson's Disease — Birmingham, Alabama
- 18F-mFBG Cardiac Uptake With Lewy Body Dementia — Houston, Texas
- Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease — Allston, Massachusetts
- GBPDC: Gut-Brain in PD Consortium Master Protocol — Stanford, California
Explore by condition: All Parkinson Disease (PD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.